Gottlieb: Valsartan API Crisis Spurs Drug GMP Revision
Executive Summary
FDA commissioner discloses effort underway to tighten oversight of changes to active pharmaceutical ingredient manufacturing processes by rewriting parts of its drug GMP regulation.